BHVN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biohaven Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for alleged violations of federal securities laws, claiming that the company made materially false and misleading statements regarding its business and operations [1][2]. Class Definition - The lawsuit seeks to recover damages for all individuals and entities that purchased Biohaven securities between March 24, 2023, and May 14, 2025, inclusive [2]. Case Details - The Complaint alleges that Defendants overstated the regulatory prospects of troriluzole as a treatment for SCA and the efficacy of BHV-7000 for bipolar disorder, which could significantly negatively impact Biohaven's business and financial condition [3]. Next Steps - Investors who suffered losses in Biohaven have until September 12, 2025, to request to be appointed as lead plaintiff in the case [4]. Cost Structure - The law firm represents investors on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5]. Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that has recovered hundreds of millions of dollars for investors in securities fraud class actions [6].